Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers

Posted by |2020-01-21T02:30:08-08:00January 17th, 2020|

Cancer research has revealed proteins known to play a role in the disease, but with no known way of stopping what they do. In pharmaceutical parlance, they’re “undruggable.” Revolution Medicines is trying to drug the undruggable with small molecules that block the signaling pathways these proteins use to help cancer grow and thrive. With one […]

BioCryst Pharma Promotes Charles Gayer to Chief Commercial Officer

Posted by |2020-01-16T15:21:22-08:00January 16th, 2020|

BioCryst Pharmaceuticals (NASDAQ: BCRX) has promoted Charles Gayer to chief commercial officer. Gayer joined the Durham, NC-based drug developer in 2015 as vice president of global strategic marketing. His experience also includes positions at Talecris and GlaxoSmithKline (NYSE: GSK). BioCryst is preparing for the expected commercial launch of berotralstat, a drug that has been submitted […]

Disarm Therapeutics Names Scott Holmes Chief Financial Officer

Posted by |2020-01-15T16:22:15-08:00January 15th, 2020|

Disarm Therapeutics has appointed Scott Holmes to serve as its chief financial officer, the same position he held most recently at Kiadis Pharma. Before working at Kiadis, Holmes was the CFO of Keryx Biopharmaceuticals. Cambridge, MA-based Disarm is developing drugs neurodegenerative disease drugs that target a protein called SARM1.

Daré Bioscience Inks Deal With Bayer for Non-Hormonal Contraceptive

Posted by |2020-01-13T22:33:33-08:00January 13th, 2020|

Daré Bioscience launched in 2015 with the aim of assembling a portfolio of novel women’s health products intended to pique interest from major pharmaceutical companies. Now the San Diego-based company has inked its first deal with Big Pharma, signing an agreement with German biopharma Bayer for its lead asset, a monthly non-hormonal form of birth […]

Neurocrine, in Second Epilepsy Deal, Pairs With Swiss Biotech Idorsia

Posted by |2020-01-13T02:30:07-08:00January 11th, 2020|

Neurocrine is doubling down on epilepsy, striking its second agreement in as many months with a new deal that grants it the option to license an investigational treatment for a rare form of the disease. The San Diego-based drug developer last month struck a deal with Xenon Pharmaceuticals (NASDAQ: XENE) that added an experimental treatment […]

DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs

Posted by |2020-01-09T17:32:12-08:00January 9th, 2020|

RNA medicines can treat some diseases by hitting targets otherwise considered “undruggable” by small molecules and biologics, but protecting the nucleic acids from degradation and getting the therapies to where they are needed in the body can be difficult. San Diego startup DTx Pharma has raised $10.6 million to advance technology it has developed that […]

Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy

Posted by |2020-01-08T17:03:19-08:00January 8th, 2020|

Food gurus tout the benefits of eating spinach and kale, but some people are better off leaving them on the plate. A molecule in these leafy greens contributes to hyperoxaluria, a condition characterized by kidney stones at first and serious organ damage later. Novome Biotechnologies is developing a gut microbiome treatment for hyperoxaluria. The company […]

Novo Holdings Repositions Antibiotics Funding Amid “Deteriorated” Market

Posted by |2020-01-07T18:17:39-08:00January 7th, 2020|

Novo Holdings is repositioning the strategic focus of its REPAIR Fund in order to provide later-stage support to its portfolio companies, as the struggling antibiotics industry faces a dearth of investment. The Danish investor launched its REPAIR Impact Fund in 2018. An acronym for “Replenishing and Enabling the Pipeline for Anti-Infective Resistance,” the fund has […]

BioIntervene Raises $30M to Move Nerve Pain Drug Into the Clinic

Posted by |2020-01-06T21:30:54-08:00January 6th, 2020|

In the past seven years BioIntervene has been working to develop “ultra-selective” compounds to target an adenosine receptor associated with pain relief. Now the San Diego-based biotech has $30 million and a chief scientific officer, Charles Cohen, to guide its lead compound, BIO-205, into human testing for neuropathic pain. The company announced the Series A […]

Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More

Posted by |2020-01-06T02:30:09-08:00January 3rd, 2020|

In the week leading up to Christmas, six drugs won FDA approvals. The decisions covered insomnia, migraine, and several different forms of cancer. The FDA’s final tally for the year totaled 48 new drug approvals. If you’re keeping score, that compares with 59 approvals in 2018 and 46 in 2017. Most of the nods went to […]

After Antitrust Challenges, Illumina and PacBio Throw in Towel on Merger

Posted by |2020-01-02T22:21:45-08:00January 2nd, 2020|

DNA sequencing machine maker Illumina will have to find another way to “read” long pieces of genetic material as well as short stretches, the genomic giant’s bailiwick. Its $1.2 billion proposal to acquire long-read capability by buying rival Pacific Biosciences ended Thursday following challenges from antitrust regulators. The deal foundered about 14 months after the […]

Investors Go With Gut Ahead of Microbiome Therapy Boom, Says Seventure

Posted by |2020-01-01T03:00:23-08:00January 1st, 2020|

French VC firm Seventure is raising over €200 million in a second dedicated fund focused on the microbiome and says the therapeutic space will mature within the next three years. In March, France’s Seventure announced it is looking to raise €200 million ($220 million) in its Health for Life Capital II fund dedicated to the […]
Load More Posts